Clinical trial
A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01489371 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Lead sponsor
- Gynecologic Oncology Group
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 9, 2012
- Completion date
- January 27, 2018
- Enrollment
- 16 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, ovarian undifferentiated carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma